Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business Results

ALISO VIEJO, Calif., May 8, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and six months ended March 31, 2013.


Quarterly Financial Highlights

  • Total company net revenues of $17.4 million
  • Gross and net NUEDEXTA® sales increased to $20.8 million and $16.5 million, respectively, representing growth of 14% and 11% versus the previous quarter
  • Cash, cash equivalents, and restricted investments of $70.2 million as of March 31, 2013.
  • "Avanir achieved a major milestone with the exciting news regarding the positive CHMP opinion for NUEDEXTA in Europe. This is a significant moment in the evolution of the company towards its goal of becoming a leading mid-cap biopharmaceutical company," said Keith A. Katkin, president and CEO of Avanir.  "Additionally, we continue to execute in the U.S. as demonstrated by our commercial and clinical progress. We enter the second half of fiscal 2013 with strong momentum, a broad CNS pipeline and a continued focus on building our business."

    Fiscal 2013 Second Quarter Results

  • Total net revenues for the quarter ended March 31, 2013 were $17.4 million, compared with $10.0 million for the comparable quarter in fiscal 2012, representing 74% year-over-year growth. Total net revenues consist of NUEDEXTA net revenue and royalty revenue from Abreva®.
  • Total operating expenses, excluding cost of sales and share-based compensation were $30.1 million in the second quarter of fiscal 2013, compared with $25.3 million in the comparable period in fiscal 2012.
  • Cash used in operations was $9.6 million in the second quarter of fiscal 2013.
  • Net loss for the fiscal 2013 second quarter was $16.5 million, or $0.12 per share, compared with a net loss of $17.0 million, or $0.13 per share, for the same period in fiscal 2012.
  • Fiscal 2013 Six-Month Results

  • Total net revenues for the first six-months of fiscal 2013 totaled $34.0 million, compared with $17.2 million for the first six months of fiscal 2012.
  • Total operating expenses, excluding cost of sales and share-based compensation were $55.4 million in the first six-months of fiscal 2013, compared to $47.0 million in the comparable period for fiscal 2012.
  • Cash used in operations was $22.3 million in the first six months of fiscal 2013.
  • Net loss for the first six-months of fiscal 2013 was $28.6 million, or $0.21 per share, compared with a net loss of $33.0 million, or $0.25 per share for the comparable period in fiscal 2012.
  • NUEDEXTA Revenue
    For the quarter ended March 31, 2013, the company reported NUEDEXTA gross and net revenue of $20.8 million and $16.5 million respectively. Second quarter fiscal 2013 NUEDEXTA net revenue increased 81% versus the previous year and 11% over the previous quarter.

    Cash, Cash Equivalents & Marketable Securities
    As of March 31, 2013 Avanir had cash, cash equivalents and restricted investments totaling $70.2 million, including cash and cash equivalents of $67.9 million.

    Business Highlights

  • The company reported an eighth consecutive quarter of NUEDEXTA unit growth in both business channels with 13% retail and 4% institutional growth.
  • The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for NUEDEXTA, recommending it be approved in two dosage strengths for the treatment of pseudobulbar affect (PBA), irrespective of neurologic cause.
  • The company appointed Corinne Nevinny, a seasoned life sciences executive with broad healthcare industry experience, to the company's board of directors.
  • Note to Investors: As previously announced, Avanir will hold a conference call to discuss fiscal 2013 second quarter financial results today, May 8, 2013, beginning at 1:30 p.m. Pacific Time. You can listen to this call by dialing 1- 877 703 6106 for domestic callers or +1- 857 244 7305 for international callers, and entering passcode 62763985. Those interested in listening to the conference call live via the internet may do so by visiting

    About NUEDEXTA
    NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

    NUEDEXTA Important Safety Information
    NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state.

    Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias.

    NUEDEXTA and certain other medicines can interact, causing serious side effects. If you take certain drugs or have certain heart problems, NUEDEXTA may not be right for you.

    NUEDEXTA causes dose-dependent QTc prolongation. When initiating NUEDEXTA in patients at risk for QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation should be conducted at baseline and 3-4 hours after the first dose.

    The most common adverse reactions are diarrhea, dizziness, cough, vomiting, asthenia, peripheral edema, urinary tract infection, influenza, increased gamma-glutamyltransferase, and flatulence. NUEDEXTA may cause dizziness.

    These are not all the risks from use of NUEDEXTA. Please refer to full Prescribing Information at

    About Avanir Pharmaceuticals, Inc.
    Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit

    AVANIR® and NUEDEXTA® are trademarks or registered trademarks of Avanir Pharmaceuticals, Inc. in the United States and other countries.

    ©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

    Forward Looking Statements
    Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Avanir's plans, potential opportunities, financial or other expectations, projections, goals objectives, milestones, strategies, market growth, timelines, legal matters, product pipeline, clinical studies, product development and the potential benefits of its commercialized products and products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Avanir's operating performance and financial position, the market demand for and acceptance of Avanir's products domestically and internationally, research, development and commercialization of new products domestically and internationally, obtaining additional indications, obtaining and maintaining regulatory approvals domestically and internationally, and other risks detailed from time to time in the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

    Avanir Investor & Media Contact
    Ian Clements, PhD
    +1 (949) 389-6700

     AVANIR PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETSMarch 31,September 30,20132012(unaudited)(audited)ASSETSCurrent assets:Cash and cash equivalents

    $  67,859,426$   69,778,406Restricted cash and cash equivalents

    654,624652,913Trade receivables, net

    9,679,7757,231,759Inventories, net

    428,969415,475Prepaid expenses and other current assets

    2,570,0742,434,590Restricted short-term investment

    -401,550Total current assets

    81,192,86880,914,693Restricted long-term investments

    1,303,9381,302,136Property and equipment, net

    1,680,3171,808,594Non-current inventories, net

    908,366908,364Other assets

    625,1961,078,009TOTAL ASSETS$  85,710,685$   86,011,796LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable, accrued expenses and other liabilities

    $  20,734,658$   15,598,666Current portion of note payable

    7,812,0142,162,263Current portion of deferred royalty revenues

    2,557,4642,557,464Total current liabilities

    31,104,13620,318,393Accrued expenses and other liabilities, net of current portion

    1,073,265666,179Note Payable

    21,325,05526,698,263Deferred royalty revenues, net of current portion

    117,0221,491,854Total liabilities

    53,619,47849,174,689Total stockholders' equity

    32,091,20736,837,107TOTAL LIABILITIES AND STOCKHOLDERS'  EQUITY$  85,710,685$   86,011,796 AVANIR PHARMACEUTICALS, INC.CONDENSED STATEMENT OF OPERATIONSThree Months Ended March 31,Six Months Ended March 31,2013201220132012REVENUESNet product sales

    $  16,535,059$
    9,141,873$   31,414,321$   14,630,636Revenues from royalties

    899,129898,5152,525,1392,574,635Revenue from research grant services

    --15,000-Total revenues

    17,434,18810,040,38833,954,46017,205,271OPERATING EXPENSESCost of product sales

    933,426534,3451,771,555844,148Cost of research grant services

    69,090-78,488-Research and development

    8,874,2986,395,15515,522,38910,139,670Selling and marketing

    16,061,40814,814,01329,583,82728,596,850General and administrative

    6,978,6845,346,99113,517,08710,639,173Total operating expenses

    32,916,90627,090,50460,473,34650,219,841Loss from operations(15,482,718)(17,050,116)(26,518,886)(33,014,570)OTHER INCOME (EXPENSE)Interest income

    15,0657,88234,39622,173Interest expense

    (1,059,245)-(2,118,490)-Other, net

    197751974,081Loss before provision for income taxes(16,526,701)(17,042,159)(28,602,783)(32,988,316)Provision for income taxesNet loss and comprehensive loss$ (16,526,701)$ (17,042,159)$ (28,602,783)$ (32,988,316)Basic and diluted net loss per share$
    (0.25)Basic and diluted weighted average number of common shares outstanding 


    SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call
    2. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
    4. AVANIR Pharmaceuticals To paticipate in two conferences in March
    5. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
    6. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
    7. Avanir Pharmaceuticals Announces Date Of Fiscal 2013 First Quarter Financial Results And Conference Call
    8. Avanir Pharmaceuticals Reports Fiscal 2012 Fourth Quarter And Year-End Financial And Business Results
    9. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
    10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
    11. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
    Post Your Comments:
    (Date:8/7/2017)... GAITHERSBURG, Md. , Aug. 7, 2017 /PRNewswire/ ... for healthcare member acquisition, retention, and engagement, announced ... Director of Strategy and Product Development, effective as ... strategic consulting and technology implementation strategy for our ... years of experience in consulting and business analytics ...
    (Date:8/7/2017)... 7, 2017  Endo International plc (NASDAQ: ... resolve virtually all known U.S. mesh product liability claims ... the known remaining U.S. claims at reasonable values. Under ... the fourth quarter of 2017 and continuing through the ... quarter 2017 results, the Company intends to increase its ...
    (Date:8/2/2017)... , Aug. 2, 2017 Fenita ... Who as a Pinnacle Lifetime Professional in the ... Account Manager at Turing Pharmaceuticals, AG. Her skills ... and relationship building.                ... than 25 years of experience as a highly ...
    Breaking Medicine Technology:
    (Date:8/17/2017)... ... August 17, 2017 , ... CareAcademy, ... that it has raised $1.675 M in seed funding to further expand its ... and Techstars Venture Capital Fund are the company’s primary investors. , ...
    (Date:8/17/2017)... ... , ... Centrifugation is more than just spinning. Like a car in our ... do without. And just like a car, there are a few points to consider ... will learn about the most important safety aspects while using a centrifuge, as well ...
    (Date:8/16/2017)... ... , ... The next Patient Care Academy at Kalamazoo Valley Community College begins ... the seven-week long Patient Care Academy are eligible to take the State of Michigan ... CNA in Kalamazoo is $24,428.* , As a CNA, one is equipped for employment ...
    (Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, the leading ... was acquired by Advantage Solutions. The Data Council’s IX-ONE platform is the ... industry’s leading suppliers, brokers, distributors and retailers. The Data Council will become a ...
    (Date:8/16/2017)... ... August 16, 2017 , ... QualDerm Partners , ... development, today announced Cumberland Skin Surgery and Dermatology has joined the ... offices in both Hermitage and Lebanon, Tennessee, provides comprehensive general dermatology and skin ...
    Breaking Medicine News(10 mins):